Healthcare
Acarix AB (publ)(ACIXF)
Live Price
Offline$0.029
+0.00% today
1Y Change
+21.15%
Window
Jun 25, 2025 β Jun 15, 2026
- Market Cap
- $300.00M
- Revenue Growth
- +18.4%
- EPS Growth
- +46.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars Β· Jun 25, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Acarix AB (publ) (ACIXF) is a Healthcare stock with a market cap of $300.00M and listed on OTC. The stock last traded around $0.03 and up 21.1% across the available one-year price window (Jun 25, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +18.4%, EPS growth of +46.7%, a dividend yield of 0.0%. What stands out right now is revenue +18.4%, EPS +46.7%, free cash flow +23.7% with operating margin -652.3% and ROIC -125.8%. Valuation already assumes a fairly strong business story at price/sales 40.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ACIXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.4% vs +7.6% peer median
Operating Margin
Below sector median
-652.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on May 18, 2026 with revenue ahead of estimates by 0.0%.
The operating story is still moving forward
Revenue is running at +18.4% and EPS at +46.7%, with operating margin around -652.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | β | +0.0% | +0.0% | +17.5% |
2026 Feb 12, 2026 | β | +0.0% | -2.9% | -29.7% |
2025 Nov 5, 2025 | β | +17.8% | +1.5% | -14.8% |
Benchmark Edge
ACIXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ACIXF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ACIXF Max Drawdown
-49.02%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ACIXF and SPY.
Company Overview
Acarix AB (publ)
Other OTC
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out in Sweden and internationally. It offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced AI to analyse the patient's coronary blood flow. The company was founded in 2009 and is headquartered in MalmΓΆ, Sweden.
- Leadership
- Aamir Mahmood
- IPO Date
- Dec 7, 2022
- Employees
- 8
- Street Address
- World Trade Center
- Mailing
- MalmΓΆ, 211 19
- Region
- MalmΓΆ, SE
- Reporting Currency
- USD
- Investor Line
- +45 44 41 44 41
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 40.4
- Price/Book
- 7.9
Growth
- Revenue
- +18.4%
- EPS
- +46.7%
- Free Cash Flow
- +23.7%
Profitability
- Gross Margin
- 73.0%
- Operating Margin
- -652.3%
- Net Margin
- -653.4%
- ROE
- -104.4%
- ROIC
- -125.8%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 4.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.